Senators again point to AbbVie as a poster child for reform. Only this time, the Dems are aiming for a low, low tax rate – Endpoints News
ALS is an debilitating, universally deadly disease. When motor neurons die, patients lose the ability to walk, cut their own food, swallow and eventually breathe. Most patients die within three to five years after the onset of symptoms, and there are few approved treatments that only to a modest extent affect function and survival.
Although patients and advocates have gathered around an experimental drug from Amylyx Pharmaceuticals, which is now being evaluated by the FDA, they continue to emphasize how more work needs to be done. Research on ALS pathology is still small compared to other fields, as researchers have not yet discovered a confirmed biomarker that measures patients̵[ads1]7; progress and have only identified a handful of genetic targets involved in the disease.
Continue reading Endpoints with a free subscription
Unlock this story instantly and join over 145,100 biopharmaceutical professionals who read Endpoints daily – and it’s free.
